Mark Talamonti to Survival Analysis
This is a "connection" page, showing publications Mark Talamonti has written about Survival Analysis.
Connection Strength
0.750
-
Quality of pancreatic cancer care at Veterans Administration compared with non-Veterans Administration hospitals. Am J Surg. 2007 Nov; 194(5):588-93.
Score: 0.057
-
Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer. 2007 Sep 15; 110(6):1227-34.
Score: 0.057
-
Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007 Aug 15; 110(4):738-44.
Score: 0.056
-
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007 Oct; 205(4):558-63.
Score: 0.056
-
Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol. 2007 Aug; 34(4):311-20.
Score: 0.056
-
Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg. 2007 Mar; 193(3):389-93; discussion 393-4.
Score: 0.055
-
Merging claims databases with a tumor registry to evaluate variations in cancer mortality: results from a pilot study of 698 colorectal cancer patients treated at one hospital in the 1990s. Cancer Invest. 2004; 22(2):225-33.
Score: 0.044
-
Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003 Oct; 134(4):720-7; discussion 727-9.
Score: 0.043
-
Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg. 2002 May; 137(5):564-70; discussion 570-1.
Score: 0.039
-
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol. 2000 Oct 01; 18(19):3384-9.
Score: 0.035
-
Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function. Surgery. 2017 11; 162(5):1032-1039.
Score: 0.028
-
A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer. J Gastrointest Surg. 2016 Feb; 20(2):284-92.
Score: 0.025
-
Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2014 Dec; 156(6):1504-10; discussion 1510-1.
Score: 0.023
-
Locally advanced carcinoma of the colon and rectum involving the urinary bladder. Surg Gynecol Obstet. 1993 Nov; 177(5):481-7.
Score: 0.022
-
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013 Jan; 17(1):94-100; discussion p. 100-1.
Score: 0.020
-
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010 Jul 13; 7(7):e1000307.
Score: 0.017
-
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010 Jun 01; 101(7):587-92.
Score: 0.017
-
Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg. 2009 Sep; 13(9):1692-8.
Score: 0.016
-
Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009 May 01; 115(9):1849-58.
Score: 0.016
-
Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol. 2008 Oct 01; 26(28):4626-33.
Score: 0.015
-
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology. 2008 May; 247(2):507-15.
Score: 0.015
-
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20; 26(6):942-7.
Score: 0.015
-
Primary gastrointestinal sarcomas: analysis of prognostic factors and results of surgical management. Surgery. 2000 Oct; 128(4):604-12.
Score: 0.009
-
Results of gastric interposition for reconstruction of the pharyngoesophagus. Surgery. 1999 Oct; 126(4):666-71; discussion 671-2.
Score: 0.008
-
Cystic neoplasms of the pancreas. A clinicopathologic study, including DNA flow cytometry. Arch Surg. 1995 Oct; 130(10):1048-54.
Score: 0.006